New hope for tough prostate cancer? drug combo enters early trial

NCT ID NCT06616155

Recruiting now Disease control Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether adding ruxolitinib to the standard drug enzalutamide can help men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The study will enroll 20 participants to find the safest dose and check for early signs of tumor shrinkage. The goal is to see if blocking certain proteins (JAK1 and JAK2) can make the cancer more sensitive to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ruxolitinib and enzalutamide
What this could lead to: If successful, this combination could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong: This is a very early, small trial (20 people) focused on safety and dosing. The combination may not work better than existing treatments, and side effects could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION-RESISTANT PROSTATE CARCINOMA METASTATIC PROSTATE ADENOCARCINOMA STAGE IVB PROSTATE CANCER AJCC V8

Contacts and locations

Locations

Karmanos Cancer Institute
NOT_YET_RECRUITING

Detroit, Michigan, 48201, United States
Rush University
NOT_YET_RECRUITING

Chicago, Illinois, 60612, United States
University of Michigan Comprehensive Cancer Center
RECRUITING

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.